Your browser doesn't support javascript.
loading
Massive hypertriglyceridemia associated with paclitaxel; a case report.
Koneshamoorthy, Anojian; Hulse, Danielle; Yuen Chong, Chia; Krishnamurthy, Balasubramanian; Ananda, Sumitra; Hamblin, Peter S.
Afiliação
  • Koneshamoorthy A; Department of Endocrinology and Diabetes, Western Health, Melbourne, Australia.
  • Hulse D; Department of Endocrinology and Diabetes, Western Health, Melbourne, Australia.
  • Yuen Chong C; Department of Medical Oncology, Western Health, Melbourne, Australia.
  • Krishnamurthy B; Department of Endocrinology and Diabetes, Western Health, Melbourne, Australia.
  • Ananda S; St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia.
  • Hamblin PS; Department of Medical Oncology, Western Health, Melbourne, Australia.
Gynecol Oncol Rep ; 42: 101030, 2022 Aug.
Article em En | MEDLINE | ID: mdl-35782104
ABSTRACT
This report describes a patient who developed massive hypertriglyceridemia (12,488 mg/dL or 141 mmol/L) during paclitaxel and carboplatin adjuvant chemotherapy for high grade serous fallopian tube carcinoma. Paclitaxel was thought to be the causative agent and she had normal triglyceride levels following a change to carboplatin and gemcitabine. To our knowledge, this is the highest reported triglyceride level associated with paclitaxel. Measurement of serum lipids should be considered in individuals receiving taxane chemotherapy, especially in those with type 2 diabetes mellitus or a history of dyslipidemia.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article